Qatar Cardiovascular Biorepository of AF Patients

January 2, 2019 updated by: Hamad Medical Corporation

Qatar Cardiovascular Biorepository-AF (QCBio-AF) Study

Qatar Cardiovascular Biorepsoitory-AF (QCBio-AF) of plasma and DNA of Qatari patients with atrial fibrillation (AF) is to establish. AF cases will include patients with acute and chronic AF identified in the Heart Hospital (HH) arrhythmia clinics and Emergency Room (ER). Controls will include blood donors who have no history of AF. Such a resource will enable validation of biomarkers to assess AF risk, response to therapy, and prognosis. QCBio-AF will also allow genomic, marker and proteomic studies of AF and response to drug therapy (pharmacogenetics and pharmacoproteomics). This study will accomplish the following specific aims: Aim 1: Establish a DNA and plasma biorepository (QCBio-AF) of 300 Qatari AF cases and Family members to enable investigation of genomic and proteomic biomarkers for early detection and prognostication and to identify new targets for drug development. Aim 2: Annotate the biorepository of with 1) demographic, laboratory, and clinical variables derived from the EMR using electronic phenotyping algorithms, and 2) detailed information regarding history of cardiovascular diseases and risk factors derived from patient surveys. Aim 3: Develop processes to promote use of the biorepository by Qatari investigators by facilitating access to the biorepository for biomarker research, while maintaining the highest ethical standards with emphasis on patient confidentiality and stewardship of the biospecimens. Timeline. Following IRB approval, the intended collection period will be over 12 months where 300 Qatari patients with AF and their immediate families will be recruited. Significance: Although atrial fibrillation (AF) is reaching epidemic proportions in the aging U.S. and European populations, the worldwide burden of AF in non-white populations is unknown. Furthermore, a substantial proportion of AF in the population is not explained by traditional risk factors. There is increasing evidence that susceptibility to AF is not only determined by underlying etiologic risk factors but also ethnicity with AF occurring more frequently in white than in non-white populations. While reasons for this ethnic variability are unknown, studies have shown that both common and rare genetic variants increase susceptibility to AF in an individual in the presence of ethnic-specific risk factors.

Study Overview

Status

Unknown

Conditions

Detailed Description

Atrial Fibrillation Epidemic and the Need for Improved Therapies: Atrial fibrillation (AF) has become a disease of global epidemic proportions due to the burgeoning population of elderly individuals. The global burden of AF was recently estimated at 33.5 million with progressive increases in incidence, prevalence and AF-related mortality having major implications for healthcare costs and public health policy. This study also highlighted regional variation in AF burden between developed versus developing countries. The number of persons in the U.S. with AF by the year 2050 is projected to exceed 16 million. The socioeconomic impacts of AF are substantial, as are the consequences of frequent visits to the emergency room (ER) and hospitalizations, chronic disease management and loss of productivity. Moreover, managing patients with AF remains challenging. Despite recent advances in catheter-based and surgical treatments, antiarrhythmic drugs (AADs) remain the mainstay of treatment for patients with symptomatic AF. However, membrane active drugs are incompletely and unpredictably effective and can be proarrhythmic. Furthermore, the selection of an AAD for an individual patient is based not only on efficacy as on minimizing the risk of adverse effects. The limited success of AADs in maintaining sinus rhythm is related in part to the heterogeneity of the underlying substrate, poor understanding of the pathophysiology of AF and our failure to target therapy to underlying mechanisms. Thus, an overarching goal of this proposal is to create and utilize a clinical and genetic database for AF to examine the role of novel and established risk factors for AF in diverse ethnic populations and determine the role of common AF susceptibility loci in two ethnic groups and examine gene-environment interactions between ethnic specific risk factors and AF.

Genetic Epidemiology of AF, in 1943, first report of familial AF in three brothers with early onset AF published. Since then many epidemiologic studies have shown that AF is heritable especially the form of AF that occurs without underlying cardiac or systemic disease - previously termed lone but is now designated as early onset AF. As the heritability of AF has been estimated to be 62%, there is a substantial genetic component to the arrhythmia. While some of loci influencing this estimate may be pleiotropic and related to other risk factors such as hypertension and diabetes that are also highly heritable, there are also several discovered and likely many undiscovered genetic risk factors that are primary determinants of early onset AF. Many genes and several AF loci have now been identified for Mendelian forms of early onset AF. In 1997, Brugada and colleagues identified the first AF locus on chr10q22; since then four other loci have been identified, including a new locus on chr5p15 identified by us that was associated with a prolonged P-wave duration. In addition, linkage analyses have identified individual mutations in several familial AF kindreds. The first AF gene (KCNQ1), identified in 2003, encodes a cardiac potassium channel current (IKs). This discovery was followed by the identification of other potassium and cardiac ion channels important in the pathophysiology of AF. The first non-ion channel AF gene (natriuretic peptide precursor A [NPPA]), was identified by linkage analysis and a positional cloning approach and encodes for atrial natriuretic peptide (ANP).

With the discovery of KCNQ1 as an AF gene, investigators then applied a candidate gene approach and identified many more rare 'private' genetic variants in other cardiac ion channel genes in familial AF kindreds. In 2007, Otway and colleagues identified a KCNQ1 mutation (R14C) in one family with familial AF. When the mutation was expressed in a heterologous expression system, the IKs current amplitude at baseline was unchanged but demonstrated marked increase compared to wild-type (WT) channels when exposed to hypotonic solution. Importantly, only those subjects with left atrial (LA) dilatation developed AF. These findings and Vanderbilt data showing that penetrance of rare AF-associated variants is modulated by common AF risk alleles at the chr4q25 locus support the concept of a two-hit genetic model for the development of AF. Mutations in genes encoding connexins, proteins important in transmitting electrical activity between cardiac myocytes, have also been identified stemming from early work in mice with null alleles for GJA5, encoding mutations in several familial AF kindreds. The first AF gene (KCNQ1), identified in 2003, encodes a cardiac potassium channel current (IKs). This discovery was followed by the identification of other potassium and cardiac ion channels important in the pathophysiology of AF. The first non-ion channel AF gene (natriuretic peptide precursor A [NPPA]), was identified by linkage analysis and a positional cloning approach and encodes for atrial natriuretic peptide (ANP).

Epidemiology of AF in Qatar: The burden of AF in populations of Middle Eastern Arabs remains unknown. Researchers explored the etiology and pattern of AF in Middle Eastern Arabs and South Asians living in Qatar using the CCS Registry at HMC26 and showed that, in this population, AF is more common in those that are older, have a history of HTN, CHF, DM and valvular heart disease. Furthermore, they showed that the incidence of AF in Middle Eastern Arab patients was significantly higher than in South Asians (12% vs. 8%) and this was mostly due to older age, a greater prevalence of HTN, and DM in the Arabs. The Registry was also used to compare the clinical demographics, and management of AF in Middle Eastern Arab in Qatar. Over 2800 Arabs and 500 South Asians were admitted for evaluation and management of AF over the 20-year period. Middle Eastern Arabs with AF were older, and had a greater prevalence of HTN, DM, chronic renal insufficient and hyperlipidemia. In contrast, South Asians were more likely to have acute coronary syndromes and a history of valvular heart disease. Importantly the in-hospital mortality rate was higher in Arabs than South Asians but the stroke rates were comparable. These studies highlight the differential impact of traditional risk factors on the development of AF in Middle eastern Arabs.

Identification of probands and families with early-onset AF in Qatar: Two Middle Eastern Arab families have been identified with early-onset AF. In one family, three family members besides the proband presented with highly symptomatic AF at age <40 years. In the second family, six family members have presented with early-onset AF. These findings are very preliminary evaluations and upon approval of the submitted protocol by the IRB Ethics Committee, further evaluations of these two families will take place.

Participant recruitment and enrollment: Patients who are over the age of 18 years presenting with early-onset AF from cardiology clinics, the ER and in-patient services from the HMC network of hospitals (Hamad General Hospital, Hamad Heart Hospital, Al-Khor Hospital, Cuban Hospital, and Al-Wakra Hospital). The HMC hospital network provides both outpatient and in-patient cardiology services for all Qatar residents, and >95% of all cardiac patients in the country are treated at these hospitals, including patients with acute cardiac conditions, representing essentially a population-based cohort for identification and selection of AF patients and a control cohort of non-AF cardiology patients for the genetic studies. These participants will comprise two broad ethnic groups that have not been adequately studied previously, defined as: Qatari and other Middle Eastern Arabs. A diagnosis of AF will be confirmed when an ECG shows AF during the index hospitalization/ER visit showing AF. Patients with a history of AF only in the setting of cardiac surgery will be excluded from this study.

For this proposal, only family members of Qatari Middle Eastern Arab patient with early onset (≤60 years of age) AF will be targeted for recruitment. In 2016, over 600 patients with AF were seen in the Hamad General Hospital ER and over 400 patients were seen by Dr. Nidal Assad (LPI) in the Arrhythmia Clinic at the Hamad Heart Hospital. Approximately 30% of these patients presented with early-onset AF. A projected annual growth of over 20% in new patients with AF will not only increase the likelihood of meeting our target recruitment but will also significantly improve our chances of identifying large kindreds with familial AF. At the same network of hospitals during the same time period, It will identify a cohort of cardiology patients without AF to be followed prospectively and to serve as a comparison group for genetic analyses. This control cohort will be a representative sample of the population of cardiology patients who do not have AF, which is already available from another completed cardiology biorepository. Patients will not be enrolled if major difficulties with follow-up are anticipated, for example, patients with no valid residency permit or those planning to leave the country before the next planned follow-up visit.

Subject Population(s) Total number of QCBio-AF participants: 300 Age range of participants: 18 yrs and above Targeted number of males: 150 Targeted number of females: 150 A informed consent will be indicated to recruit patients who may be eligible for the study.

Participant Identification, Inclusion/Exclusion Criteria, and Recruitment Patients will be identified through Hamad Medical Corporation (HMC) Heart Hospital (HH) Arrhythmia and General Cardiology Clinics and the Emergency Department will be approached for inclusion in the study. A detailed family history and a DNA sample will then be obtained by the principal investigator or a research coordinator, following written informed consent under a protocol approved by the Institutional Review Board of HMC. Upon identification of a patient with a family history of AF, relatives will be contacted by the by the principal investigator or a research coordinator. Once this is obtained, outside medical records will be requested.

Identify the criteria for inclusion and exclusion and explain the procedures that will be used to determine eligibility:

Specimen Collection for the main study:

Blood drawing (indicate total amount drawn for research purposes): 25 cc x 1 (one-time only).

Other specimens (describe the type of specimen and frequency of collection): None Study-specific questionnaires will be conducted at enrollment, and when appropriate and available, collected at the subjects' six-month and 12-month scheduled clinic visits. The questionnaires will take approximately take 10 minutes to complete. These are only applicable to adult patients.

The baseline, 6-month, and 12-month questionnaires and other information from the medical record will be collected at regularly scheduled clinic visits on study-specific source documentation to later be transcribed onto SPSS with only the subject's study-specific code ID/number assigned to the data.

The ECG, ECHO, and Holter monitoring will be performed (or will have already been performed) as part of the subjects' clinically indicated treatment/management for their AF. Family members asked to participate in the study who do not have a documented history of AF will not have the ECG, ECHO, and Holter monitoring performed because it is not clinically indicated. Family members who are not part of the UIC medical system and have had an ECG, ECHO, and/or Holter monitoring performed at outside facilities will be asked to provide this information for research purposes only.

The creation of a Qatar Cardiovascular Biorepsoitory-AF (QCBio-AF): a resource that will collect and store clinical, demographic, blood and DNA samples from patients and family members with AF to enable subsequent clinical, molecular, and genetic studies.

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Qatar
      • Doha, Qatar, 3050
        • Heart Hospital, Hamad Medical Coorporation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Qatari subjects must have a documented history of AF or atrial flutter by ECG, ECHO, and or Holter monitor event recorder. Subjects' family members approached for the study may or may not have a documented history AF.

Description

Inclusion Criteria:

  1. Age >=18 years
  2. History of AF and without
  3. Atrial flutter by ECG, ECHO or Holter monitor event recorder
  4. Willing to give written informed consent.

Exclusion Criteria:

  1. AF or atrial flutter associated with cardiac surgery
  2. Pregnant females (at the baseline visit) and prisoners.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of KCNQ1 Gene expression in AF
Time Frame: One year
Establish a DNA and plasma biorepository (QCBio-AF) of 300 Qatari AF cases and Family members to enable investigation of genomic and proteomic biomarkers for early detection and prognostication and to identify new targets for drug development
One year
Incidence of AF in diverse ethnic population
Time Frame: One year
Risk factors for AF in diverse ethnic population
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hamad Medical Corporation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 1, 2019

Primary Completion (Anticipated)

March 1, 2020

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

July 24, 2018

First Submitted That Met QC Criteria

September 4, 2018

First Posted (Actual)

September 6, 2018

Study Record Updates

Last Update Posted (Actual)

January 3, 2019

Last Update Submitted That Met QC Criteria

January 2, 2019

Last Verified

July 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MRC-01-17-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe